- Home
- SGI vs GMAB Comparison
SGI vs GMAB Comparison
Compare SGI & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGI
- GMAB
- Stock Information
- Founded
- SGI 1846
- GMAB 1999
- Country
- SGI United States
- GMAB Denmark
- Employees
- SGI N/A
- GMAB N/A
- Industry
- SGI Home Furnishings
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- SGI Consumer Discretionary
- GMAB Health Care
- Exchange
- SGI Nasdaq
- GMAB Nasdaq
- Market Cap
- SGI 13.3B
- GMAB 13.7B
- IPO Year
- SGI N/A
- GMAB N/A
- Fundamental
- Price
- SGI $69.71
- GMAB $20.72
- Analyst Decision
- SGI Strong Buy
- GMAB Buy
- Analyst Count
- SGI 4
- GMAB 9
- Target Price
- SGI $69.00
- GMAB $39.17
- AVG Volume (30 Days)
- SGI 2.2M
- GMAB 1.5M
- Earning Date
- SGI 08-18-2025
- GMAB 08-07-2025
- Dividend Yield
- SGI 0.88%
- GMAB N/A
- EPS Growth
- SGI N/A
- GMAB 276.80
- EPS
- SGI 1.50
- GMAB 18.36
- Revenue
- SGI $5,346,200,000.00
- GMAB $3,230,902,140.00
- Revenue This Year
- SGI $51.72
- GMAB $747.74
- Revenue Next Year
- SGI $6.08
- GMAB $14.81
- P/E Ratio
- SGI $45.46
- GMAB $1.13
- Revenue Growth
- SGI 8.96
- GMAB 25.43
- 52 Week Low
- SGI $45.04
- GMAB $17.24
- 52 Week High
- SGI $70.65
- GMAB $28.56
- Technical
- Relative Strength Index (RSI)
- SGI N/A
- GMAB 41.92
- Support Level
- SGI N/A
- GMAB $20.39
- Resistance Level
- SGI N/A
- GMAB $20.75
- Average True Range (ATR)
- SGI 0.00
- GMAB 0.32
- MACD
- SGI 0.00
- GMAB -0.23
- Stochastic Oscillator
- SGI 0.00
- GMAB 7.98
About SGI Somnigroup International Inc. Common Stock
Somnigroup International Inc is a bedding company, dedicated to improving people's lives through better sleep. With superior capabilities in design, manufacturing, distribution and retail, It delivers breakthrough sleep solutions and serves the evolving needs of consumers in more than 100 countries worldwide through its fully-owned businesses, Tempur Sealy, Mattress Firm and Dreams. The company's portfolio includes the brand such as Tempur-Pedic, Sealy and Stearns & Foster, and its Multinational omnichannel platform enables the company to meet consumers wherever shop, offering a personal connection and innovation to provide a retail experience and tailored solutions.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.